Study Finds Obesity Drug Wegovy Reduces Risk of Heart Problems, Expanding Potential Uses
A groundbreaking study has revealed that the obesity drug Wegovy has the potential to reduce the risk of severe heart problems by 20%, broadening its applications beyond weight loss. Driven by Dr. Michael Lincoff from the Cleveland Clinic, the study recently presented its findings at the American Heart Association conference and published them in the esteemed New England Journal of Medicine.
The research, sponsored by Wegovy’s manufacturer Novo Nordisk, examined over 17,600 participants from 41 countries. All participants were 45 years old or older, had preexisting cardiovascular disease, and a body mass index (BMI) of 27 or higher. Half of the participants were administered weekly injections of Wegovy, while the other half received a placebo shot. The participants were closely monitored for an average of over three years.
The results of the study were remarkable. Of those who received Wegovy injections, only 6.5% experienced heart attack, stroke, or death from a heart-related cause, compared to 8% of those who received the placebo shot. Additionally, Wegovy participants observed improvements in inflammation, cholesterol levels, blood sugars, and blood pressure, indicating that the drug’s effects extend beyond weight loss.
This study’s findings are particularly significant because Wegovy is a high-dose version of the drug Ozempic, which has previously demonstrated its ability to reduce the risk of serious heart issues in people with diabetes. However, this study focused solely on individuals without diabetes, highlighting the power of Wegovy on a broader scale.
Despite the positive results, participants did report experiencing major side effects while on Wegovy, including nausea, vomiting, diarrhea, and strange dreams. These side effects led approximately 17% of those on Wegovy to discontinue their treatment.
One major concern associated with obesity medications like Wegovy is their high cost. Wegovy along with Eli Lilly’s Zepbound can range from $1,000 to $1,300 per month, making them inaccessible for many individuals. Additionally, insurance coverage for these drugs is limited, further exacerbating the issue.
In light of these findings, Novo Nordisk has officially requested the Food and Drug Administration to include the heart benefits of Wegovy on its label, similar to Ozempic’s labeling. This move seeks to increase awareness among healthcare professionals and enable more patients to access this potentially life-saving treatment.
The results of this pivotal study represent a significant step forward in the fight against obesity-related heart problems. With further research and the potential for expanded insurance coverage, Wegovy could become a vital tool in reducing the risk of severe heart issues and improving overall cardiovascular health.
“Infuriatingly humble tv expert. Friendly student. Travel fanatic. Bacon fan. Unable to type with boxing gloves on.”